Analystreport

Allogene Therapeutics, Inc. (NASDAQ: ALLO) had its price target lowered by analysts at Truist Financial Co. to $29.00.

Allogene Therapeutics, Inc.  (ALLO) 
Last allogene therapeutics, inc. earnings: 2/27 04:30 am Check Earnings Report